Emerging therapies for juvenile arthritis: agents in early clinical trials

References

• Martini A, Lovell D, Albani S, et al., Juvenile idiopathic arthritis. Nat Rev Dis Prim. 2022;8(1): 5.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(369):767–778.
   PubMedGoogle Scholar
• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–2149.
   PubMed Web of Science ®Google Scholar
• Petty R, Southwood T, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: durban, 1997. J Rheumatol. 1998;25(10):1991–1994.
   PubMedGoogle Scholar
• Petty R, Southwood T, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child. 2011;96(6):596–601.
   PubMed Web of Science ®Google Scholar
• Martini A, Ravelli A, Avcin T, et al., Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2): 190–197.
   PubMed Web of Science ®Google Scholar
• Lee J, Eng S, Guzman J, et al. A comparison of juvenile idiopathic arthritis classification systems with the research in arthritis in Canadian children, emphasizing outcomes (ReACCh-Out) cohort. Arthritis Rheumatol. 2022;74(8):1409–1419.
   PubMedGoogle Scholar
• Nigrovic P, Colbert R, Holers V, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021;17(5):257–269.
   PubMed Web of Science ®Google Scholar
• Vastert S, Kuis W, Grom A. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655–664.
   PubMed Web of Science ®Google Scholar
• Rosina S, Natoli V, Santaniello S, et al. Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2021;17(8):853–870.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Grom AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289–298.
   PubMed Web of Science ®Google Scholar
• Zaripova L, Midgley A, Christmas S, et al. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Vesely R, Saint-Raymond A, et al. PRINTO. Impact of the European paediatric legislation in paediatric rheumatology: past, present and future. Ann Rheum Dis. 2013;72(12):1893–1896.
   PubMed Web of Science ®Google Scholar
• Tremouler AH, Albani S. Novel therapies for rheumatoid arthritis. Expert Opin Investig Drugs. 2006;15(11):1427–1441.
   PubMed Web of Science ®Google Scholar
• Semerano L, Thiolat A, Minichiello E, et al. Targeting IL-6 for the treatment of rheumatoid arthritis: phase II investigational drugs. Expert Opin Investig Drugs. 2014;23(7):979–999.
   PubMed Web of Science ®Google Scholar
• Semerano L, Decker P, Clavel G, et al. Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs. 2016;25(12):1355–1359.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu Z, Yu Q, et al. Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to II clinical trials. Expert Opin Investig Drugs. 2019;28(12):1113–1123.
   PubMed Web of Science ®Google Scholar
• Brunner H, Schanberg L, Kimura Y, et al. New medications are needed for children with juvenile idiopathic arthritis. Arthritis Rheumatol. 2020;72(11): 1945–1951.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Giancane G, Alongi A, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Heal. 2019;3(4):255–263.
   Web of Science ®Google Scholar
• Viola S, Felici E, Magni-Manzoni S, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(7):2092–2102.
   PubMedGoogle Scholar
• Giancane G, Muratore V, Marzetti V, et al. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther. 2019;21(1):168.
   PubMedGoogle Scholar
• Kolomeyer A, Crane E, Tu Y, et al. Adult patients with uveitis associated with juvenile idiopathic arthritis: a retrospective review. Can J Ophthalmol. 2017;52(5):458–462.
   PubMed Web of Science ®Google Scholar
• Haasnoot A, Vernie L, Rothova AVD, et al. Impact of juvenile idiopathic arthritis associated uveitis in early adulthood. PLoS One. 2016;11(10):e0164312.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Consolaro A, Horneff G, et al., Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6): 819–828.
   PubMed Web of Science ®Google Scholar
• Onel K, Horton D, Lovell D, et al., 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res. 2022;74(4): 521–537.
   Web of Science ®Google Scholar
• Onel K, Horton D, Lovell D, et al. 2021 American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Arthritis Care Res. 2022;74(4):505–520.
   Web of Science ®Google Scholar
• Ringold S, Angeles-Han S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol. 2019;71(6):846–863.
   PubMed Web of Science ®Google Scholar
• Angeles-Han S, Ringold S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Rheumatol. 2019;71(6):864–877.
   PubMed Web of Science ®Google Scholar
• Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352(16):1655–1666.
   PubMed Web of Science ®Google Scholar
• Burgos-Vargas R, Vázquez-Mellado J, Pacheco-Tena C, et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61(10):941–942.
   PubMed Web of Science ®Google Scholar
• Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160–3169.
   PubMed Web of Science ®Google Scholar
• Martini A, Lovell D. Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis. 2010;69(7):1260–1263.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Martini A. Emerging drugs to treat juvenile idiopathic arthritis. Expert Opin Emerg Drugs. 2011;16(3):493–505.
   PubMed Web of Science ®Google Scholar
• Giancane G, Ruperto N. (PRINTO) PRITO. Treatment of juvenile idiopathic arthritis: what’s new? Curr Opin Rheumatol. 2019;31(5):428–435.
   PubMed Web of Science ®Google Scholar
• Ruperto NMA. Current and future perspectives in the management of juvenile idiopathic arthritis. Lancet Child Adolesc Heal. 2018;2(5):360–370.
   Web of Science ®Google Scholar
• Lovell D, Giannini E, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med. 2000;342(11):763–769.
   PubMed Web of Science ®Google Scholar
• Lovell D, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–820.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell D, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096–3106.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718–722.
   PubMed Web of Science ®Google Scholar
• Balevic S, Rabinovich C. Profile of Adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther. 2016;10(10):2997–3003.
   PubMedGoogle Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646.
   PubMed Web of Science ®Google Scholar
• Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003–1011.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell D, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–391.
   PubMed Web of Science ®Google Scholar
• Brunner H, Tzaribachev N, Vega-Cornejo G, et al. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Arthritis Rheumatol. 2018;70(7):1144–1154.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):60454–60457.
   Web of Science ®Google Scholar
• De Benedetti F, Brunner H, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395.
   PubMed Web of Science ®Google Scholar
• Brunner H, Ruperto N, Zuber Z, et al., Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6): 1110–1117.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner H, Ramanan A, et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatol. 2021;60(10):4568–4580.
   PubMed Web of Science ®Google Scholar
• Ramanan A, Dick A, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–41.
   PubMedGoogle Scholar
• Mallalieu N, Wimalasundera S, Hsu J, et al. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatr Rheumatol Online J. 2019;17(1):57.
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747–754.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–2406.
   PubMed Web of Science ®Google Scholar
• Ilowite N, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66(9):2570–2579.
   PubMed Web of Science ®Google Scholar
• Lovell D, Giannini E, Reiff A, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486–2496.
   PubMed Web of Science ®Google Scholar
• Grom A, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259–268.
   PubMed Web of Science ®Google Scholar
• Griffin G, Shenoi S, Hughes G. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020;34(4):101515.
   PubMed Web of Science ®Google Scholar
• Sönmez H, Demir S, Bilginer Y, et al. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. 2018;37(12):3329–3335.
   PubMed Web of Science ®Google Scholar
• Klotsche J, Raab A, Niewerth M, et al. Outcome and trends in treatment of systemic juvenile idiopathic arthritis in the German national pediatric rheumatologic database, 2000-2013. Arthritis Rheumatol. 2016;68(12):3023–3034.
   PubMed Web of Science ®Google Scholar
• Horneff G, Schulz A, Klotsche J, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256.
   PubMed Web of Science ®Google Scholar
• Vastert S, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still’s disease. Rheumatol. 2019;58(Suppl6):vi9–22.
   PubMed Web of Science ®Google Scholar
• Clarke S, Ramanan A. Tofacitinib in juvenile idiopathic arthritis. Lancet. 2021;398(10315):1943–1945.
   PubMed Web of Science ®Google Scholar
• Vieira M, Zwillich S, Jansen J, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. Clin Ther. 2016;38(12):2628–2641.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner H, Zuber Z, et al., Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J. 2017;15(1): 86.
   PubMedGoogle Scholar
• Ruperto N, Brunner H, Synoverska O, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398(10315):1984–1996.
   PubMed Web of Science ®Google Scholar
• Huizinga T, Fleischmann R, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73(9):1626–1634.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Calvo Penadés I, Rubio-Pérez N, et al. Sarilumab, a human monoclonal antibody to the interleukin-6 receptor, in polyarticular-course juvenile idiopathic arthritis: a 12-week, multinational, open-label, dose-finding study [abstract]. Arthritis Rheumatol. 2019;71(Suppl10).
   Google Scholar
• Weinblatt M, Mease P, Mysler E, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ra. Arthritis Rheumatol. 2015;67(10):2591–2600.
   PubMed Web of Science ®Google Scholar
• Smolen J, Weinblatt M, Sheng S, et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73(9):1616–1625.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Foeldvari I, Alexeeva E, et al. LB0004 Efficacy and safety of secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: primary results from a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 study (JUNIPERA). Ann Rheum Dis. 2021 Jun 1;80(Suppl 1): 201 LP – 202.
   Google Scholar
• Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018;77(6): 840–847.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nakagishi Y, Inoue N, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015;160(2):277–281.
   PubMed Web of Science ®Google Scholar
• Yasin S, Fall N, Brown RA, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology (Oxford, England). 2020;59(2):361–366.
   PubMed Web of Science ®Google Scholar
• Yasin S, Solomon K, Canna S, et al. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatol. 2020;59(2):442–445.
   PubMed Web of Science ®Google Scholar
• Romberg N, Vogel T, Canna S. NLRC4 inflammasomopathies. Curr Opin Allergy Clin Immunol. 2017;17(6):398–404.
   PubMed Web of Science ®Google Scholar
• Bracaglia C, De Graaf K, Marafon DP, et al., Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterize patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76(1): 166–172.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brogan P, Grom A, et al. Emapalumab, an interferon gamma-blocking monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA). In: Proceedings of the EULAR MeetingMadrid. 2019.
   Google Scholar
• Martini A. Are there new targets for juvenile idiopathic arthritis? Semin Arthritis Rheum. 2019;49(3):S11–3.
   PubMedGoogle Scholar
• De Benedetti F, Brogan P, Bracaglia C, et al. OP0290 emapalumab (anti-interferon-gamma monoclonal antibody) in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA). Ann Rheum Dis. 2020;79(Suppl1):180.
   Google Scholar
• European Commission. State of paediatric medicines in the EU: 10 years of the EU paediatric regulation. Report from the Commission to the European Parliament and the Council. 2017.
   Google Scholar
• O’Dell J, Mikuls T, Taylor T, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–318.
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66(2):228–234.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis. 2013;72(1):3–6.
   PubMed Web of Science ®Google Scholar
• Yeung R, Albani S, Feldman B, et al. Enhancing translational research in paediatric rheumatology through standardization. Nat Rev Rheumatol. 2016;12(11):684–690.
   PubMed Web of Science ®Google Scholar
• Smolen J, Aletaha D, Bijlsma J, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637.
   PubMed Web of Science ®Google Scholar
• Smolen J, Breedveld F, Burmester G, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.
   PubMed Web of Science ®Google Scholar
• Nigrovic P. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405–1413.
   PubMed Web of Science ®Google Scholar
• Ter Haar N, van Dijkhuizen E, Swart J, et al., Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 2019;71(7): 1163–1173.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Landewé R, Smolen J. Review of head-to-head study designs in rheumatoid arthritis. Semin Arthritis Rheum. 2016;46(3):279–285.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(4):1263–1271.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Xie F, Chen L, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773–2780.
   PubMed Web of Science ®Google Scholar
• Becker I, Horneff G. Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in pediatric rheumatology registry. Arthritis Care Res (Hoboken). 2017;69(4):552–560.
   PubMed Web of Science ®Google Scholar
• Swart J, Giancane G, Horneff G, et al., Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018;20(1): 1–11.
   PubMedGoogle Scholar
• Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the food and drug administration. Arthritis Rheum. 2010;62(8):2517–2524.
   PubMed Web of Science ®Google Scholar
• Horneff G, Klein A, Oommen P, et al. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER registry. Clin Exp Rheumatol. 2016;34(6):1113–1120.
   PubMed Web of Science ®Google Scholar
• Mannion M, Beukelman T. What is the background incidence of malignancy in children with rheumatic disease? Curr Rheumatol Rep. 2013;15(3):310.
   PubMed Web of Science ®Google Scholar
• Nordstrom B, Mines D, Gu Y, et al. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res. 2012;64(9):1357–1364.
   PubMed Web of Science ®Google Scholar
• Barbier L, Ebbers H, Declerck P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734–755.
   PubMed Web of Science ®Google Scholar
• Renton W, Leveret H, Guly C, et al. Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2019;17(1):67.
   PubMed Web of Science ®Google Scholar
• Brunner H, Rider L, Kingsbury D, et al. Pediatric rheumatology collaborative study group – over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatr Rheumatol Online J. 2018;16(1):45.
   PubMedGoogle Scholar